Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
NCT07295132Phase 2Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Dec 2025
- Primary completion
- Nov 2029
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Asan Medical Center. Primary endpoint: Progression-Free Survival at 24 months. Planned start Dec 2025; status: not yet recruiting.
02
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07295132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295132.